Status:
TERMINATED
Sulfation of Bile Acids as a Biomarker for Hepatobiliary Diseases
Lead Sponsor:
University of Nebraska
Conditions:
Hepatobiliary Diseases
Eligibility:
All Genders
19-65 years
Brief Summary
The investigators hypothesize that the extent of sulfation of toxic BAs and their urinary elimination can be used as a biomarker to predict the severity and prognosis of hepatobiliary diseases. The in...
Detailed Description
The investigators propose the following specific aims to test the investigators hypothesis: Specific Aim #1: Establish a baseline of individual and total urinary BAs and BA-sulfates in healthy contro...
Eligibility Criteria
Inclusion
- Healthy Controls
- Male or female, age 19-65, no apparent signs of hepatobiliary diseases
Exclusion
- Levels higher than 50, 56, 78 U/L for ALT, AST, and GGT, respectively.
- Patient Population
- Inclusion Criteria:
- Male or female, age 19-65, visiting the UNMC hepatology clinic for treatment from hepatobiliary diseases
Key Trial Info
Start Date :
November 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 2 2022
Estimated Enrollment :
430 Patients enrolled
Trial Details
Trial ID
NCT01200082
Start Date
November 1 2011
End Date
September 2 2022
Last Update
October 2 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Nebraska Medial Center
Omaha, Nebraska, United States, 68198